

Cynomolgus SerpinC1 / AntithrombinIII / ATIII Protein (His Tag)

Catalog Number: 90042-C08H



Sino Biological Inc.

Biological Solution Specialist

General Information

Gene Name Synonym:

SerpinC1

Protein Construction:

A DNA sequence encoding the Cynomolgus (Macaca fascicularis) SerpinC1 (Met 1-Ser 464) was fused with a polyhistidine tag at the C-terminus.

Source: Cynomolgus

Expression Host: Human Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Bio-Activity

Measured by its ability to inhibit thrombin cleavage of a fluorogenic peptide substrate Boc-VPR-AMC, R&D Systems, Catalog# ES011. The IC50 value is

Endotoxin:

< 1.0 EU per µg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Ser 35

Molecular Mass:

The recombinant cynomolgus SerpinC1 consists of 441 amino acids and has a calculated molecular mass of 50.2 kDa. The apparent molecular mass of the recombinant protein is approximately 55-60 kDa in SDS-PAGE under reducing conditions due to glycosylation.

Formulation:

Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.


Usage Guide

Storage:

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

SDS-PAGE:



Reconstitution:

Detailed reconstitution instructions are sent along with the products.

Protein Description

SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization.

References

1. Chandra, T. et al., 1983, Proc. Natl. Acad. Sci. 80: 1845-1848.
2. Perry, D.J. et al., 1994, Blood. Rev. 8: 37-55.
3. Chuang, Y.J. et al., 2001, Biochemistry. 40: 6670-6679.
4. Saito, H. et al., 2005, J. Leukoc. Biol. 78: 777-784.
5. Oelschlager, C. et al., 2002, Blood. 99: 4015-4020.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Fax :+86-10-51029969 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>